Lutz Wollin

Years Active: 2019-2022
Publications (10 Years): 5

Boehringer Ingelheim Pharma GmbH and Co KG Biberach

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Boehringer Ingelheim Pharma GmbH and Co KG Biberach Apr 01 2020

Germany

Biomarker Expert :: Translational Medicine and Clinical Pharmacology

Publications

Jorge Alonso-Pérez, Ana Carrasco-Rozas, Maria Borrell-Pages, Esther Fernández-Simón, Patricia Piñol-Jurado, Lina Badimón, Lutz Wollin, Cinta Lleixà, Eduard Gallardo, Montse Olivé, Jordi Díaz-Manera, Xavier Suárez-Calvet
Nintedanib Reduces Muscle Fibrosis and Improves Muscle Function of the Alpha-Sarcoglycan-Deficient Mice. Biomedicines 10 (10) (2022)
Christina Hesse, Valerie Beneke, Sebastian Konzok, Claudia Diefenbach, Jannie Marie Bülow Sand, Sarah Rank Rønnow, Morten Asser Karsdal, Danny Jonigk, Katherina Sewald, Armin Braun, Diana Julie Leeming, Lutz Wollin
Nintedanib modulates type III collagen turnover in viable precision-cut lung slices from bleomycin-treated rats and patients with pulmonary fibrosis. Respiratory research 23 (1) (2022)
Nessrine Bellamri, Roselyne Viel, Claudie Morzadec, Valérie Lecureur, Audrey Joannes, Bertrand de Latour, Francisco Llamas-Gutierrez, Lutz Wollin, Stéphane Jouneau, Laurent Vernhet
TNF-α and IL-10 Control CXCL13 Expression in Human Macrophages. Journal of immunology (Baltimore, Md. : 1950) 204 (9) (2020)
Lutz Wollin, Dieudonnée Togbe, Bernhard Ryffel
Effects of Nintedanib in an Animal Model of Liver Fibrosis. BioMed research international 2020 (2020)
Lutz Wollin, Jörg Hw Distler, Christopher P Denton, Martina Gahlemann
Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis-associated interstitial lung disease. Journal of scleroderma and related disorders 4 (3) (2019)

Lutz Wollin.css-eqlu8i{font-size:small;padding-left:4px;}